TAAP Act advances without altering FDA scientific review standards.

A proposed law called the TAAP Act is moving forward in Congress. It would create new ways for people — especially veterans — to access psychedelic treatments. Importantly, it wouldn't lower the bar for proving a drug is safe and effective; the FDA (the US drug regulator) would still apply the same rigorous scientific tests.

Legislation shapes access pathways and funding, not evidentiary thresholds. Congress rarely dictates division-level review criteria.